REG-4basebio Plc: Director Dealing

4BasebioAnnouncement

22/05/2026 09:15

4basebio PLC
("4basebio" or the "Company")

 

Director Dealing

 

CAMBRIDGE, UK – 22 May 2026                               –             
       4basebio PLC (AIM: 4BB), a company pioneering an enzymatically-produced
DNA technology serving the next generation genetic medicines markets,
announces that on 21 May 2026 it was informed that Dr. Amy Walker, Chief
Executive Officer of the Company, purchased 1,863 ordinary shares in the
capital of the Company through the market.            

 

Further details are set out in the Notification of Dealing Form below.

 

 Director / PCA  Number of ordinary shares urchased  Purchase price (pence)  Shareholding following purchase  Shareholding following purchase as a % of the issued share capital  
 Dr. Amy Walker  1,863                               509.00                  48,529                           0.31%                                                               

 

The 1,863 shares purchased represent approximately 0.01 per cent. of the
Company's issued share capital.

 

The issued share capital of the Company comprises 15,538,518 ordinary shares.

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse
(Amendment) (EU Exit) Regulations 2019/310.

For further enquiries, please contact:

 4basebio PLC                                                 
 Dr Amy Walker, CEO                                           
 +44 (0)12 2396 7943                                          
 Cairn Financial Advisers LLP (Nominated Adviser)             
 Jo Turner / Sandy Jamieson / Ed Downes  +44 (0)20 7213 0880  
                                                              
 Cavendish Capital Markets Limited (Joint Broker)             
 Geoff Nash / Nigel Birks  +44 (0)20 7220 0500                
                                                              
 RBC Capital Markets (Joint Broker)                           
 Kathryn Deegan / Matthew Coakes  +44 (0)20 7653 4000         
                                                              
 ICR Healthcare (Media and Investor Relations)                
 Mary-Jane Elliott / Jessica Hodgson  +44 (0)203 707 5700     

 

 

About 4basebio

4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the
use of synthetic DNA to enable next-generation therapeutics and vaccines.
Through its proprietary enzymatic DNA synthesis platform, 4basebio produces
GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability,
overcoming the limitations of plasmid-based systems. The company offers
application-specific DNA constructs tailored to the diverse needs of gene
therapies, genome editing, mRNA production, and DNA vaccines, helping partners
accelerate proof-of-concept studies and reach clinical milestones more
efficiently while maintaining the highest standards of safety and quality.

 

For more information, visit                                  4basebio.com     
                (https://www.4basebio.com/)          .

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1   Details of the persons discharging managerial responsibilities / person closely associated                                                                                                            
 a)  Name                                                                                               Dr. Amy Walker                                                                                     
 2   Reason for the notification                                                                                                                                                                           
 a)  Position/Status                                                                                    Chief Executive Officer                                                                            
 b)  Initial notification/ Amendment                                                                    Initial notification                                                                               
 3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor                                                                                         
 a)  Name                                                                                               4basebio plc                                                                                       
 b)  LEI                                                                                                213800E2DX9EAIUNCB30                                                                               
 4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted     
 a)  Description of the financial  instrument, type of  instrument    Identification code               Ordinary Shares                                                                                    
                                                                                                           ISIN: GB00BMCLYF79                                                                              
 b)  Nature of the transaction                                                                          Acquisition of ordinary shares                                                                     
 c)  Price(s) and volume(s)                                                                             Price: 509.00p    Volume: 1,863                                                                    
 d)  Aggregated information    -       Aggregated volume      -       Aggregated Price                  See above                                                                                          
 e)  Date of transaction                                                                                21 May 2026                                                                                        
 f)  Place of transaction                                                                               London Stock Exchange                                                                              

 

 



Copyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved